Ratio Examination: Biogen Inc (BIIB)’s Price-to-Cash and Price-to-Free Cash Flow

The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.

In the latest session, Biogen Inc (NASDAQ: BIIB) closed at $138.86 up 2.17% from its previous closing price of $135.91. In other words, the price has increased by $2.17 from its previous closing price. On the day, 1.44 million shares were traded. BIIB stock price reached its highest trading level at $139.58 during the session, while it also had its lowest trading level at $136.02.

Ratios:

For a deeper understanding of Biogen Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.38 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.29. For the most recent quarter (mrq), Quick Ratio is recorded 1.79 and its Current Ratio is at 2.50. In the meantime, Its Debt-to-Equity ratio is 0.37 whereas as Long-Term Debt/Eq ratio is at 0.37.

On April 28, 2025, HSBC Securities Downgraded its rating to Hold which previously was Buy but kept the price unchanged to $118.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 08 ’25 when Izzar Rachid sold 2,223 shares for $135.00 per share. The transaction valued at 300,105 led to the insider holds 6,330 shares of the business.

Izzar Rachid bought 2,223 shares of BIIB for $300,105 on Jul 08 ’25. On May 19 ’25, another insider, Singhal Priya, who serves as the Head of Development of the company, sold 3,806 shares for $126.25 each. As a result, the insider received 480,508 and left with 5,427 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BIIB now has a Market Capitalization of 20358959104 and an Enterprise Value of 23762190336. As of this moment, Biogen’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.28, and their Forward P/E ratio for the next fiscal year is 8.78. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.12 while its Price-to-Book (P/B) ratio in mrq is 1.15. Its current Enterprise Value per Revenue stands at 2.377 whereas that against EBITDA is 7.374.

Stock Price History:

The Beta on a monthly basis for BIIB is 0.11, which has changed by -0.3265108 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, BIIB has reached a high of $207.59, while it has fallen to a 52-week low of $110.04. The 50-Day Moving Average of the stock is 6.45%, while the 200-Day Moving Average is calculated to be 0.01%.

Shares Statistics:

For the past three months, BIIB has traded an average of 1.45M shares per day and 1440600 over the past ten days. A total of 146.60M shares are outstanding, with a floating share count of 146.34M. Insiders hold about 0.19% of the company’s shares, while institutions hold 89.76% stake in the company. Shares short for BIIB as of 1753920000 were 3959672 with a Short Ratio of 2.74, compared to 1751241600 on 4000596. Therefore, it implies a Short% of Shares Outstanding of 3959672 and a Short% of Float of 3.49.

Earnings Estimates

Currently, 24.0 analysts are dedicated to thoroughly evaluating and rating the performance of Biogen Inc (BIIB) in the stock market.The consensus estimate for the next quarter is $3.46, with high estimates of $4.32 and low estimates of $2.81.

Analysts are recommending an EPS of between $16.18 and $13.92 for the fiscal current year, implying an average EPS of $15.72. EPS for the following year is $15.81, with 32.0 analysts recommending between $17.81 and $13.98.

Revenue Estimates

A total of 24 analysts believe the company’s revenue will be $2.33B this quarter.It ranges from a high estimate of $2.45B to a low estimate of $2.26B. As of the current estimate, Biogen Inc’s year-ago sales were $2.47BFor the next quarter, 24 analysts are estimating revenue of $2.26B. There is a high estimate of $2.44B for the next quarter, whereas the lowest estimate is $2.14B.

A total of 33 analysts have provided revenue estimates for BIIB’s current fiscal year. The highest revenue estimate was $10.03B, while the lowest revenue estimate was $9.09B, resulting in an average revenue estimate of $9.62B. In the same quarter a year ago, actual revenue was $9.68BBased on 33 analysts’ estimates, the company’s revenue will be $9.27B in the next fiscal year. The high estimate is $9.74B and the low estimate is $8.46B.

Leave a Reply

Your email address will not be published. Required fields are marked *

DWinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.